- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04820335
Promoting Independence With Compensatory Cognitive Rehabilitation
Promoting Independence With Compensatory Cognitive Rehabilitation: A Pilot Clinical Trial for Early-Stage Alzheimer's Disease
Alzheimer's disease (AD) is one of the leading causes of disability in older adults. Because pharmacological approaches do not seem to prevent or slow the disease, clinicians need non-pharmacological interventions that might help people with AD remain independent for as long as possible. This study aims to evaluate the effects of a new behavioral treatment, the Structured External Memory Aid Treatment (SEMAT), for adults with mild cognitive impairment (MCI) designed to promote independent living skills by explicitly teaching the use of strategies and tools to compensate for cognitive weaknesses.
Aim 1: Evaluate the efficacy of the SEMAT for improving functional performance in a pilot randomized trial.
Aim 2: Evaluate demographic, clinical, and neuropsychological predictors of treatment adherence.
Aim 3: Develop and refine the SEMAT manual and other materials for training future interventionists.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Clinical Trial Study Design: Pilot Individually Randomized Group-Treatment Trial
Study Site: University of Delaware. All research activities will occur via telehealth.
Study Participants: Approximately 65 older adults will be recruited to participate to ensure 50 completers with MCI. Participants will be recruited and complete study procedures in waves.
Randomization: Following the screening criteria session and informed consent, if the participant met the criteria for amnestic MCI he/she will be randomly assigned to the immediate treatment or delayed treatment control condition.
Study Procedures Aim 1: Clinical Trial. Once randomly assigned to a condition, participants will complete baseline testing and additional testing at two other time periods: weeks 8 and 16. Participants in the immediate treatment condition will then complete 7-weeks of the group SEMAT. At week 8, participants in both groups will complete assessments. Then, those in the delayed treatment group will complete 7-weeks of treatment. At week 16, participants in both conditions will complete assessments. During assessment sessions, participants will complete performance-based and self-reported measures of independent daily tasks and tests of thinking and memory independently with an assessor for approximately 1 hour. During treatment sessions (approximately 60 minutes), participants will interact with group-mates and learn how use three different categories of external memory aids. Treatment sessions will be video recorded and transcribed.
- Aim 2a: The 50 participants with MCI who are enrolled in Aim 1 activities will also be included in Aim 2. Participants will complete additional self-report measures of efficacy and depression prior to the active phase of treatment either during baseline or week 8 (Aim 1).
- Aim 2b: The investigators will randomly select a subpopulation of participants with single-domain aMCI (n=15) and multi-domain aMCI (n=15), as well as their study partners (n=15; n=15) to complete cognitive interviewing immediately following completion of the active phase of the intervention (Aim 1). Participants will engage in semi-structured interviews that will take approximately 1 hour and will be video recorded, transcribed, and qualitatively analyzed for themes that are discussed.
Study Duration: Each participant will be involved for approximately 18 weeks (including screening criteria session and cognitive interviews, if applicable)
Retention of Subjects: The investigators will stagger participant payments and over recruit.
Control condition: No treatment
Intervention: The Structured External Memory Aid Treatment (SEMAT): A 7-week treatment that will teach three categories of external memory aids to participants to help compensate for everyday memory challenges. This is a behavioral intervention.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Delaware
-
Newark, Delaware, United States, 19716
- Recruiting
- University of Delaware
-
Contact:
- Alyssa M Lanzi, Ph.D.
- Phone Number: 302-831-0420
- Email: mwm-research@udel.edu
-
Principal Investigator:
- Alyssa M Lanzi, Ph.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
- 60-90 years of age
- English Speaking
- Functional Vision and Hearing to Complete Phone Screen
- not taking or stable ( >2 months) on nootropic meds
- amnestic mild cognitive impairment from probable Alzheimer's disease
Exclusion Criteria
- History of major psychiatric disorder (e.g. schizophrenia)
- Untreated major depression
- History of medical diseases that are related to cognitive impairment
- current participation in another clinical trial related to memory
- major auditory, visual, or motor impairment that would affect their ability to participate in the study
- substance use disorder in the past 5 years
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Immediate Treatment Group
Participants will complete 7, 60-minute SEMAT sessions over 7 weeks with their group.
|
During the 7 weeks of treatment, the interventionist will teach 3 categories of external memory aids (calendars, timers, notes) following an already-developed detailed treatment manual (described here briefly). Week 1: Introduction of External Memory Aid Treatment and Person-Centered Goal Setting. Weeks 2-7. In the next six weeks, three categories of external memory aids will be taught: calendars, timers, and notes. The focus of the first session will be how to use the strategies, and the second session will build awareness of when to use these strategies during everyday tasks. Within each category, three types of strategies will be taught to participants. Within each session, learning phases will follow training stages from compensatory learning theory: 1) acquisition phase, 2) application phase, and 3) an adaptation phase.
Other Names:
|
No Intervention: Delayed Treatment Control
Participants will not receive the intervention immediately.
After 8 weeks, participants in this arm will complete the SEMAT.
This is not a crossover design, because the treatment effects from those in the immediate treatment group can not be taken away.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Memory Based Everyday Function
Time Frame: Baseline to immediately post-treatment
|
The Everyday Cognition (ECog) is a questionnaire to assess improvements in memory based everyday functioning.
The ECog comprises of 39 items on which the participant's current level of everyday functioning is compared to a pervious level.
Items are rated on a four-point scale: 1= better or no change; 4= consistently much worse.
Higher scores indicate greater functional limitations.
The self-report and informant versions will be administered.
|
Baseline to immediately post-treatment
|
Changes in Memory Based Compensation
Time Frame: Baseline to immediately post-treatment
|
Everyday Compensation (EComp) is a questionnaire to assess improvements in memory based compensation.
The EComp comprises of 41 items on which the participant's current level of strategy use is compared to a pervious level.
Items are rated on a four-point scale: 1= never; 4= always.
Higher scores indicate greater strategy use.
The self-report and informant versions will be administered.
|
Baseline to immediately post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Everyday Strategy Use
Time Frame: Baseline to immediately post-treatment
|
The Functional External Memory Aid Tool, a performance-based assessment tool of attempted compensation and task accuracy.
The development of this tool is described above (Preliminary Data).
Participants can score a maximum of 33 points on the 11-item FEMAT, representing successful use of compensatory strategies to complete everyday tasks.
|
Baseline to immediately post-treatment
|
Changes in Cognitive Abilities
Time Frame: Baseline to immediately post-treatment
|
The Dementia Rating Scale-2 (DRS-2) will be administered to assess a patient's overall level of cognition.
The test includes 5 subtests to examine domains of Attention, Initiation/Perseveration, Construction, Conceptualization, and Memory.
|
Baseline to immediately post-treatment
|
Changes in Quality of Life
Time Frame: Baseline to immediately post-treatment
|
The QOL-AD will be administered.
This is a patient-reported outcome measure that assesses global domains of quality of life.
The self-report and informant versions will be administered.
The questionnaire is 13 items that are rated on a 4-point rating scale.
Higher scores indicate greater quality of life.
|
Baseline to immediately post-treatment
|
Changes in Executive Functioning Skills
Time Frame: Baseline to immediately post-treatment
|
The BRIEF-A will be administered.
This is a patient-reported outcome measure that assesses global and individual domains of executive functions.
The self-report and informant versions will be administered.
The questionnaire is 75 items that are rated on a 3-point rating scale.
Lower scores indicate greater executive functions.
|
Baseline to immediately post-treatment
|
Changes in Self Efficacy
Time Frame: Baseline to immediately post-treatment
|
The Memory Loss Self Efficacy Scale will be used to assess self-reported self efficacy specific to memory loss.
The patient and study partner versions will be administered.
The Memory Loss Self-Efficacy Scale is 9-items rated on a 10-point scale (1-not at all confident to 10-confident).
Higher scores indicate greater self-efficacy.
|
Baseline to immediately post-treatment
|
Maintained Changes in Memory Based Everyday Function
Time Frame: Immediately post-treatment to 8-weeks later
|
The Everyday Cognition (ECog) is a questionnaire to assess improvements in memory based everyday functioning.
The ECog comprises of 39 items on which the participant's current level of everyday functioning is compared to a pervious level.
Items are rated on a four-point scale: 1= better or no change; 4= consistently much worse.
Higher scores indicate greater functional limitations.
The self-report and informant versions will be administered.
|
Immediately post-treatment to 8-weeks later
|
Maintained Changes in Memory Based Compensation
Time Frame: Immediately post-treatment to 8-weeks later
|
Everyday Compensation (EComp) is a questionnaire to assess improvements in memory based compensation.
The EComp comprises of 41 items on which the participant's current level of strategy use is compared to a pervious level.
Items are rated on a four-point scale: 1= never; 4= always.
Higher scores indicate greater strategy use.
The self-report and informant versions will be administered.
|
Immediately post-treatment to 8-weeks later
|
Maintained Changes in Everyday Strategy Use
Time Frame: Immediately post-treatment to 8-weeks later
|
The Functional External Memory Aid Tool, a performance-based assessment tool of attempted compensation and task accuracy.
The development of this tool is described above (Preliminary Data).
Participants can score a maximum of 33 points on the 11-item FEMAT, representing successful use of compensatory strategies to complete everyday tasks.
|
Immediately post-treatment to 8-weeks later
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- K23AG070185 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States